Pfizer Inc. Q1 2006 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 2, 2006. Pfizer Inc. is a research-based global pharmaceutical company operating in Human Health, Consumer Healthcare, and Animal Health segments. The quarter was marked by the completion of the acquisition of sanofi-aventis' worldwide rights to Exubera (an inhaled insulin) for approximately $1.4 billion and the continued execution of the "Adapting to Scale" (AtS) productivity initiative.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2006 | Q1 2005 |
|---|---|---|
| Revenues | $12,660 | $13,091 |
| Net Income | $4,111 | $301 |
| Diluted EPS | $0.56 | $0.04 |
| Operating Cash Flow | $3,961 | $3,193 |
| Total Debt | $11,567 | $17,936 |
| Cash & Short-term Investments | $15,502 | $22,226 |
| Effective Tax Rate | 7.1% | 90.6% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3% year-over-year, driven by the loss of U.S. exclusivity for Zithromax (Nov 2005), continued declines in Neurontin and Diflucan, and a strengthening U.S. dollar which reduced revenues by $377 million.
- Profit Surge: Net income increased significantly from $301 million to $4.11 billion. This was primarily due to a lower effective tax rate (7.1% vs. 90.6% in 2005). The 2005 rate was inflated by a $2.2 billion charge for repatriating foreign earnings under the American Jobs Creation Act.
- Tax Benefits: In Q1 2006, Pfizer recorded a $441 million tax benefit from the resolution of a Warner-Lambert breakup fee appeal and a $217 million benefit from new IRS regulations on statutory mergers.
- Debt Reduction: Total debt decreased by approximately $6.4 billion as the company used proceeds from short-term investment redemptions to pay down borrowings.
- Restructuring Costs: Restructuring charges and merger-related costs increased to $306 million (from $219 million), largely due to the AtS initiative implementation costs ($186 million) and restructuring charges ($301 million).
Guidance, Outlook, and Risks
- 2006 Outlook: Management expects 2006 revenues to be comparable to 2005. Forecasted Adjusted Income is approximately $15.0 billion, with forecasted Reported Net Income between $11.8 billion and $12.1 billion (Diluted EPS $1.56 - $1.60).
- Product Pipeline: Key growth drivers expected to be Lipitor, Celebrex, Lyrica, and Geodon. New product launches planned for 2006 include Exubera, Sutent, Eraxis, varenicline, Zeven, and indiplon.
- Consumer Healthcare: Pfizer is exploring strategic options for its Consumer Healthcare business, including a possible sale or spin-off, with a decision expected by the end of Q3 2006.
- Risks: Significant risks include the loss of patent exclusivity for Zoloft (Q2 2006) and Norvasc/Zyrtec (2007), uncertainty surrounding COX-2 inhibitors (Celebrex/Bextra), and ongoing legal proceedings regarding asbestos (Quigley subsidiary) and product liability.
Investor Verification Checklist
- Patent Expirations: Verify the impact timeline for Zoloft (Q2 2006) and Norvasc/Zyrtec (2007) on future revenue streams.
- Tax Normalization: Confirm that the 7.1% effective tax rate is not sustainable and adjust future earnings models to reflect a normalized rate, excluding the one-time $658 million tax benefits.
- Consumer Healthcare Strategy: Monitor the decision regarding the sale or spin-off of the Consumer Healthcare segment and its potential impact on consolidated revenue.
- AtS Initiative Costs: Track the realization of the projected $2 billion in cost savings for 2006 against the $487 million in costs incurred in Q1.
- Legal Contingencies: Review the status of the Quigley asbestos bankruptcy reorganization plan and potential liabilities from Lipitor promotion litigation.